Use of diethylcarbamazine – DEC as lung and liver anti-inflammatory

Project 558

Problem to be solved

• Acute, chronicle (such as asthma), obstructive pulmonary inflammation, and fibrosis.
• Liver inflammation induced by alcoholism.

Proposed innovation

Diethylcarbamazine interferes with the metabolism of the arachidonic acid by inhibiting the enzymes of cyclooxygenase and lipoxygenase ways. It inhibits the signaling way of NF-kB significantly blocking the production of proinflammatory cytokines, acting as a potent anti-inflammatory drug.

Differential

• Presents low cost when compared with the therapies currently used.
• As it is a drug widely used in the treatment of filariasis, preclinical tests will not be necessary.
• As it does not present the side effects produced by glucocorticoids, it should act with more safety than anti-inflammatory drugs available in the market.

Stage of development

In vivo test (murine model)

What we want

Seeking partnership for conducting clinical trials and drug formulation.

Coordinator

Christina Alves Peixoto/ CPqAM

Contact

Gestec/VPPIS – phone: 21 3882 9099/ 3882 9120 or portfolio@fiocruz.br